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INFLUENCE OF INTRACELLULAR DELAY ON THE DYNAMICS
OF HEPATITIS C VIRUS
SANDIP BANERJEE∗, RAM KEVAL† , AND SUNITA GAKKHAR‡
Abstract. In this paper we present a delay induced model for hepatitis C virus incorporating
the healthy and infected hepatocytes as well as infectious and noninfectious virions. The model is
mathematically analyzed and characterized, both for the steady states and the dynamical behavior of
the model. It is shown that time delay does not affect the local asymptotic stability of the uninfected
steady state. However, it can destabilize the endemic equilibrium, leading to Hopf bifurcation to
periodic solutions with realistic data sets. The model is also validated using 12 patient data obtained
from the study, conducted at the University of Sao Paulo Hospital das clinicas.
Key words. Hepatitis C virus, Intracellular delay, Stability analysis, Bifurcation analysis.
AMS subject classifications. 92B99
1. Introduction. An overwhelming number of people globally are infected with
the hepatitis C virus (HCV). Chronic HCV often requires treatment in the form of liver
transplant [14]. Unfortunately, most of the cases of chronic HCV lead to fatalities.
The traditional treatment with pegylated interferon (IFN) has met with moderate
success. The current front line therapy for HCV involves a combination of IFN and
ribavirin [14, 18]. Even then this combination therapy elicits success in about half
of the treated cases [14] and is quite expensive. It is therefore imperative to study
the mechanism of viral dynamics and the precise extent of therapeutic response. The
eventual goal would be to improve upon the therapeutic protocols [18] keeping in mind
the goal of minimizing the viral load while also minimizing the toxic side effects [6].
As already pointed out the therapeutic effectiveness of IFN is moderate but patients
show remarkable progress when it is combined with ribavirin [18, 21]. The response to
the combination therapy has been varied in nature [14, 18]. In some cases, there has
been a sustained fall of the virus below detection levels, whereas in other cases there
has either been a fall in the viral load followed by a relapse after cession of treatment
as well as cases of complete non response [14, 18]. Even in successful cases, the viral
load has exhibited biphasic and triphasic levels of decline [10].
Mathematical models which are simple but elegant have played a pivotal role
(especially in recent years) in the understanding of the mechanism of viral dynamics
in the cases of influenza, hepatitis B and human immunodeficiency virus (HIV) [17,
30, 32, 1, 27]. One of the earliest realistic model to reflect the viral dynamics of HCV
was a work by Neumann et al. that appeared in 1998 [29]. The model [29] comprised
of a simple but coupled system of three ordinary differential equations (ODEs). It
involved the mechanism of the uninfected and the productively infected target cells
(which in case of HCV are the hepatocytes). The treatment involved only IFN and
did not include ribavirin. The hepatocytes were assumed to have a constant source
of supply and undergo a natural death. Some of these hepatocytes were rendered
into an infected state by the HCV resulting in infected hepatocytes, some of which
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were lost due to immune response. The virions were following a birth (due to infected
hepatocytes) and a natural death process [14]. The authors then incorporated into
the model the effectiveness of IFN on the viral load. It was observed that the IFN
was primarily playing the role of rendering the virions ineffective, while having a
minimal role in controlling the transition of hepatocytes from an uninfected to an
infected state. An assumption in the contrary to the previous statement, resulted
in the model showing results of a single phase delay which contradicted the clinical
results. However, when the assumption of IFN being mainly used to target the virus,
was used in the model, the results showed a close matching with the experimental
results [21, 29] of biphasic decline in the viral load. Once this model was validated
for in vivo HCV dynamics it was used to estimate key parameter values of the model.
The drawback of this model was its inability to capture the long-term behavior of
dynamics as well as it’s failure to take into account the consequences of usage of
ribavirin.
The motivation of a subsequent work was to address the issues that were left open
for deliberations in [29]. Dixit et al. [15], in an endeavor to capture the effects of
ribavirin in the dynamics, presented an improved model. In this model the presence of
ribavirin created two categories of viruses (one infectious and the other noninfectious)
owing to the understanding that the predominant role of ribavirin was to render a
fraction of the virus into a noninfectious state. The most interesting finding of this
work was the observation in numerical simulations that ribavirin has a little role to
play in the first phase of a biphasic decline of viral load. It also affects the second
phase and that too only when the effectiveness of IFN is moderate. The biological
explanation of this as provided by the authors [15] is that when IFN is effective, it
can control the virions and hence ribavirin is left with a little role to play. It is when
IFN is minimally effective that ribavirin reduces the viral load not by arresting the
virus which in turn would have affected the production of infected hepatocytes, but
because of the fact that viruses have been rendered noninfectious [14]. This model
was also successful in capturing some of the long-term effects.
While both these models [29, 15] are widely regarded as seminal work in math-
ematical modeling of HCV dynamics, they did not fully address the clinical obser-
vations of triphasic decline and more importantly, the critical issue of non-response
(which unfortunately happens in a majority of the chronic cases). These limitations
of [29, 15] were addressed in a recent work by Dahari et al. [10]. This model was an
extension of the previous models [29, 15]. The model for the first time included the
mechanism of the liver by including a logistic growth term for the hepatocytes (both
uninfected and infected) and a maximum carrying capacity which put a limit on the
proliferation of hepatocytes. They were able to obtain an elegant, yet simple criti-
cal effectiveness threshold beyond which one cannot attain sustained long time viral
decay. This threshold which was a function of both viral and host parameters, was
able to explain the rationale being the non-effectiveness of the treatment. This home-
ostatic cell proliferation terms were also able to address mathematically the causes
behind the triphasic decline observed in some patients. This model, however, still has
aspects that have to be addressed in terms of clinical validation, since the estimation
of parameters from liver mechanism still remains a gray area. A similar model has
been proposed by Banerjee et al. [2], where dynamical behavior of the HCV due to
separate efficacies of interferon and ribavirin hold the key factor.
Time delays in connection with viral dynamics, namely, HIV, Lymphocytic chori-
omeningitis virus (LCMV), Hepatitis B are always an interesting features of study
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among the researches as models of viral infection dynamics with delays may have
complicated impact on the dynamics of a system. Also, a delay in the viral pro-
duction of infected cells may drastically change the estimates of viral clearance [28].
Delay may cause the loss of stability and can bifurcate various periodic solutions
[20]. Clearly in viral dynamics, the time for viral infection is not instantaneous. De-
velopment of the mathematical model and the associated analytical and numerical
techniques that incorporate discrete time delay into the model of hepatitis C viral
dynamics is the primary motivation here.
Section 2 gives the formulation of the model in details. Section 3 deals with the
linear stability analysis and bifurcation analysis, including the estimation of the length
of delay to preserve stability, direction and stability of Hopf bifurcation. Section 4
gives the numerical results and its biological implications and the paper ends with a
discussion.
2. Model Formulation. The proposed model is the amalgamation and mod-
ification of the models that appear in [6, 2], which is represented by the system of
coupled ODEs:
dT
dt
= s+ rT
(
1−
T + I
Tmax
)
− d1T − (1− cη1)αVIT,
dI
dt
= (1 − cη1)αVIT − d2I,
dVI
dt
=
(
1−
ηr + η1
2
)
βI − d3VI ,(2.1)
dVNI
dt
=
(
ηr + η1
2
)
βI − d3VNI .
Here, T denotes the target cells (uninfected hepatocytes), I are infected hepatocytes
(productively infected cells), VI and VNI represent the infectious and non-infectious
viruses (virions) respectively. The first equation projects the growth of uninfected
hepatocytes from a constant source at a rate s, followed by an intrinsic logistic growth
term at a rate r. Please note that the logistic part is of the form rT (1−(T +I)/Tmax),
where Tmax is the carrying capacity of the hepatocytes (both infected as well as
uninfected). This is because of the fact that as the threshold value Tmax is attained,
the infected and the non-infected hepatocytes are not differentiated but considered as
a whole. As already pointed out in [10], the logistic term is incorporated to capture
the homeostatic cell proliferation. There are two drugs acting on the system, namely,
interferon and ribavirin. At this point we note that η1 is the efficacy of interferon
in blocking the release of new virions. The term (1 − cη1) (0 < c < 1) reflects the
ineffectiveness of interferon (which is much smaller than its effectiveness in blocking
the virions and which is why we take (0 < c < 1)) in inhibiting hepatocytes conversion
from the uninfected to the infected one.
The second equation gives the dynamics of infectious hepatocytes, where the
uninfected hepatocytes (T) are infected by the infectious virions (VI) at the rate α
and the whole term (1 − cn1)αVIT shifts from the uninfected class to the infected
one; (−d2I) is the natural death of the infected hepatocytes (I).
The combined effect of the interferon and ribavirin has been incorporated in the
last two equations. Due to the combined efficacy, the infectious hepatocytes replicates
into infectious (VI) as well as non-infectious (VNI) virions. The term (1−(ηr+η1)/2)βI
determines the growth of infectious virions due to non-efficacy of the combined drugs:
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interferon and ribavirin, due to which the infected cells are replicating virions at a
rate β. But, due the efficacy of the combined effect of interferon and ribavirin, the
infected cells are replicating non-infectious virions at a rate β, which is given by the
term ((ηr + η1)/2)βI, which also points out that the combined effect of the drugs
interferon and ribavirin are successful in rendering the virions from an infected state
to an uninfected one. Finally, the infectious and noninfectious viruses are assumed to
have the same natural death rate of d3. Note that here 0 < η1 < 1 and 0 < ηr < 1
lead to 0 < ((ηr + η1)/2) < 1.
It has been almost invariably observed that in viral dynamics, there is a time
delay (say, τ) in conversion of the target cells (the CD4 T-cells in case of HIV [28]
and hepatitis B viral dynamics [20] for instance) from an uninfected to an infected
stage. This delay in transformation induces delay in the growth of infected cells.
Hence, the model, which is represented by a system of coupled ODEs (equation(2.1))
is converted to a system of delay differential equations (DDEs):
dT
dt
= s+ rT
(
1−
T + I
Tmax
)
− d1T − (1− cη1)αVIT,
dI
dt
= (1 − cη1)αVI(t− τ)T (t− τ)− d2I,
dVI
dt
=
(
1−
ηr + η1
2
)
βI − d3VI ,(2.2)
dVNI
dt
=
(
ηr + η1
2
)
βI − d3VNI .
The system is subjected to initial conditions:
T (θ) = ψ1(θ), I(θ) = ψ2(θ), VI(θ) = ψ3(θ), VNI(θ) = ψ4(θ), θ ∈ [−τ, 0],
ψi(0) ≥ 0, i = 1, 2, 3, 4(2.3)
where (ψ1(θ), ψ2(θ), ψ3(θ), ψ4(θ)) ∈ C
(
[−τ, 0], R4+0
)
, the Banach space of con-
tinuous functions, mapping the interval [−τ, 0] into R4+0. We define R
4
+0 and R
4
+
(the interior of R4+0) as:
R4+0 = ((T, I, VI , VNI) : T, I, VI , VNI ≥ 0)
R4+ = ((T, I, VI , VNI) : T, I, VI , VNI > 0)
This model of DDEs will form the fundamental mathematical framework for this
paper.
3. Qualitative analysis of the model.
3.1. Equilibria and linear stability analysis. There exit two positive equi-
librium points of (2.1), namely,
1. E1 :
T̂ =
Tmax
2r
[
(r − d1) +
√
(r − d1)2 +
4rs
Tmax
]
, r > d1, I = 0, VI = 0, VNI = 0.
2. E2 :
T ∗ =
d2d3
(1− cη1)
(
1− ηr+η12
)
αβ
, I∗ =
(
sR0Tmax + rT̂
2
rT̂ + d2R0Tmax
)(
1−
1
R0
)
,
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V ∗I =
(
1−
ηr + η1
2
)
βI∗
d3
, V ∗NI =
(
ηr + η1
2
)
βI∗
d3
.
Here R0 =
T̂
T∗
is the basic reproduction number. E2 exists if R0 > 1.We assume that
s ≤ d1Tmax, so that the model is physiologically realistic.
The characteristic equation about any equilibrium point E¯(T¯ , I¯, V¯I , V¯NI) is given
by∣∣∣∣∣∣∣∣
r − d1 −
2rT¯
Tmax
− rI¯
Tmax
− (1− cη1)αV¯I − λ −
rT¯
Tmax
−(1− cη1)αT¯ 0
(1− cη1)αV¯Ie
−λτ −d2 − λ (1− cη1)αT¯e
−λτ 0
0
(
1− ηr+η12
)
β −d3 − λ 0
0
(
ηr+η1
2
)
β 0 −d3 − λ
∣∣∣∣∣∣∣∣ = 0.
(3.1)
For the equilibrium point E1 = (T̂ , 0, 0, 0), (3.1) reduces to(
λ+
2r
Tmax
√
(r − d1)2 +
4rs
Tmax
)
(λ+ d3)
[
λ2 + (d2 + d3)λ+ d2d3
(
1−R0e
−λτ
)]
= 0.
Clearly, for τ = 0, E1 is locally asymptotically stable for R0 < 1 and unstable for
R0 > 1. For τ > 0, two eigenvalues are negative and the other two are given by
λ2 + (d2 + d3)λ+ d2d3
(
1−R0e
−λτ
)
= 0.(3.2)
Case I (τ > 0, R0 > 1): Let F1(λ) = λ
2+(d2+d3)λ and F2(λ) = d2d3
(
R0e
−λτ − 1
)
,
so that F1(λ) = F2(λ). Clearly, F1(0) = 0 and F1(λ)→∞ as λ→∞; whereas F2(λ)
is decreasing in λ. Furthermore, F2(0) = d2d3 (R0 − 1) > 0 (since, R0 > 1). There-
fore, for some positive λ, the two functions F1(λ) and F2(λ) must intersect, implying
the fact that the equation (3.2) has a positive root and we conclude that E1, the
disease free steady state is unstable for positive delay and R0 > 1.
Case II (τ > 0, R0 < 1): Our expectation in this case is (3.2) possesses neg-
ative roots and the disease free equilibrium is stable. Clearly, λ2 + (d2 + d3)λ =
d2d3
(
R0e
−λτ − 1
)
does not possess a non-negative real root because F1(λ) is an in-
creasing function for λ ≥ 0, whereas F2(λ) is a decreasing function with F2(0) =
R0 − 1 < 0. Therefore, we conclude that (3.2) will have roots with non-negative real
parts if the roots are complex and should have been obtained from a pair of complex
conjugate roots, which crosses the imaginary axis [8]. This implies that for some
τ ≥ 0, (3.2) must have a pair of purely imaginary roots. Without any loss of general-
ity, let λ = iω (ω > 0) be the root of (3.2). Substituting in (3.2) and separating the
real and imaginary parts we get,
− ω2 + d2d3 = R0d2d3 cos(ωτ),
(d2 + d3)ω = R0d2d3 sin(ωτ).
Eliminating the trigonometric function we get,
(ω2)2 + (d22 + d
2
3)ω
2 + d22d
2
3
(
1−R20
)
= 0.(3.3)
Clearly, in (3.3), the sum of the roots are negative and the product of the roots are
positive (as R0 < 1) and consequently, (3.3) does not have any positive real roots,
implying that there does not exist any ω for which iω is a solution of (3.2). Following
Rouche´’s theorem [13] (Theorem 9.17.4), we conclude that all the eigen values of the
characteristic equation (3.2) have a negative real part for all τ ≥ 0. Therefore, E1 is
locally asymptotically stable for R0 < 1.
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3.2. Critical drug efficacy. The critical drug efficacy for this model is defined
as (for details see [2])
ηc = 1−
2rd2d3
αβ[(r − d1)k +
√
(r − d1)2k2 + 4rsk]
= 1−
T ∗0
T̂
where T ∗0 =
d2d3
αβ
is the number of uninfected hepatocytes in an infected person before
treatment (obtained by putting η1 = ηr = 0 in T
∗) and T̂ is the steady state of
hepatocytes in an uninfected individual. ηc gives a measure for the threshold of the
efficacies of drugs, interferon and ribavirin. If the combined efficacies exceed the
critical value, HCV are eradicated whereas if η < ηc, HCV reaches a new steady
state, lower than the previous steady state value [10, 2].
3.3. Hopf Bifurcation Analysis. For the equilibrium point E2 = (T
∗, I∗, V ∗I , V
∗
NI),
(3.1) reduces to
(λ+ d3)[λ
3 + a0λ
2 + a1λ+ a2 + (b1λ+ b2)e
−λτ ] = 0(3.4)
where,
a0 = d2 + d3 +
s
T ∗
+
rT ∗
Tmax
, a1 = d2d3 + (d2 + d3)
(
s
T ∗
+
rT ∗
Tmax
)
,
a2 = d2d3
(
s
T ∗
+
rT ∗
Tmax
)
,
b1 =
d2rI
∗
Tmax
− (1 − cη1)
(
1−
ηr + η1
2
)
αβT ∗ =
d2rI
∗
Tmax
− d2d3,
b2 =
d2d3rI
∗
Tmax
+
(
d2I
∗ − s−
rT ∗2
Tmax
)
(1 − cη1)
(
1−
ηr + η1
2
)
αβ
= d2d3I
∗
(
r
Tmax
+
d2
T ∗
)
− d2d3
(
s
T ∗
+
rT ∗
Tmax
)
.
Clearly, the characteristic equation (3.4) has one negative eigenvalue, namely, −d3
and we are left with
λ3 + a0λ
2 + a1λ+ a2 + (b1λ+ b2)e
−λτ = 0,(3.5)
a transcendental equation (3.5) which has infinitely many eigenvalues and for which
the classical Routh-Hurwitz condition for stability analysis fails.
In the absence of delay (τ = 0), the characteristic equation (3.5) becomes
λ3 + a0λ
2 + (a1 + b1)λ + (a2 + b2) = 0,(3.6)
By Routh-Hurwitz criteria, (3.6) will have negative real parts if a0 > 0, a1 + b1 > 0,
a2 + b2 > 0 and (a1 + b1)a0 − (a2 + b2) > 0. Clearly, the first three conditions hold.
Therefore, the equilibrium point E2 is asymptotically stable in the absence of delay
(τ = 0), provided[
(d2 + d3)
(
s
T ∗
+
rT ∗
Tmax
)
+
d2rI
∗
Tmax
]
×
(
d2 + d3 +
s
T ∗
+
rT ∗
Tmax
)
(3.7)
−d2d3I
∗
(
r
Tmax
+
d2
T ∗
)
> 0
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We now want to investigate the existence of purely imaginary roots of (3.5).
Putting λ = iω (ω is taken as positive) in the equation (3.5) and solving for real and
imaginary parts, we have the system of transcendental equations as
a0ω
2 − a2 = b2 cos(ωτ) + b1ω sin(ωτ)(3.8)
ω3 − a1ω = b1ω cos(ωτ)− b2 sin(ωτ)(3.9)
Squaring and adding (3.8) and (3.9), we obtain,
ω6 +A1ω
4 +A2ω
2 +A3 = 0,(3.10)
with
A1 = (a
2
0 − 2a1), A2 = (a
2
1 − b
2
1 − 2a0a2), A3 = a
2
2 − b
2
2.(3.11)
The simplest assumption that (3.10) will have a positive root is A1 > 0 and A3 < 0.
Clearly, A1 = d
2
2+d
2
3+
(
s
T∗
+ rT
∗
Tmax
)2
is positive. Therefore, for a positive root of the
equation (3.10), we simply conclude that a2 − b2 < 0, that is,
2d2d3
(
s
T ∗
+
rT ∗
Tmax
)
− d2d3I
∗
(
r
Tmax
+
d2
T ∗
)
< 0
Therefore, we can say that there exists a unique positive root ω0 satisfying (3.10),
that is, the characteristic equation (3.4) will have purely imaginary roots of the form
±iω. From (3.8) and (3.9), solving for cos(ωτ), we get
cos(ωτ) =
(a0ω
2 − a2)b2 + (ω
3 − a1ω)b1ω
b22 + (b1ω)
2
.
Then τj corresponding to ω0 is given by
τj =
1
ω0
arccos
[
(a0ω
2
0 − a2)b2 + (ω
3
0 − a1ω0)b1ω0
b22 + (b1ω0)
2
]
+
2jpi
ω0
, j = 0, 1, 2, .....(3.12)
For τ = 0, E2 is locally asymptotically stable, provided (3.7) holds, therefore, by But-
ler’s Lemma [19], E2 remains locally asymptotically stable for τ < τ0.
To establish the Hopf bifurcation at τ = τ0, we have to show the transversality
condition [
d(Reλ)
dτ
]
τ = τj
> 0.
Now, differentiating (3.5) with respect to τ , we get[
(3λ2 + 2a0λ+ a1) + e
−λτ b1 − τe
−λτ (b1λ+ b2)
] dλ
dτ
= (b1λ+ b2)e
−λτλ.
This implies [
dλ
dτ
]
−1
=
3λ2 + 2a0λ+ a1
λe−λτ (b1λ+ b2)
+
b1
λ(b1λ+ b2)
−
τ
λ
=
3λ2 + 2a0λ+ a1
−λ(λ3 + a0λ2 + a1λ+ a2)
+
b1
λ(b1λ+ b2)
−
τ
λ
=
2λ3 + a0λ
2 − a2
−λ2(λ3 + a0λ2 + a1λ+ a2)
+
−b2
λ2(b1λ+ b2)
−
τ
λ
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Therefore,
Θ = sign
[
Re
(
2λ3 + a0λ
2 − a2
−λ2(λ3 + a0λ2 + a1λ+ a2)
+
−b2
λ2(b1λ+ b2)
−
τ
λ
)]
λ = iω0
=
1
ω20
sign
[
Re
(
(a2 + a0ω
2
0) + i2ω
3
0
(a0ω20 − a2) + i(ω
3
0 − a1ω0)
+
b2
b2 + i(b1ω0)
)]
=
1
ω20
sign
[
(a2 + a0ω
2
0)(a0ω
2
0 − a2) + 2ω
3
0(ω
3
0 − a1ω0)
(a0ω20 − a2)
2 + (ω30 − a1ω0)
2
+
b22
b22 + (b1ω0)
2
]
=
1
ω20
sign
[
2ω60 + (a
2
0 − 2a1)ω
4
0 + (b
2
2 − a
2
2)
b22 + (b1ω0)
2
]
Clearly, A1 = a
2
0 − 2a1 is positive and by the assumption A3 = a
2
2 − b
2
2 is negative,
implying [
d(Reλ)
dτ
]
ω = ω0, τ = τj
> 0.
We summarize the preceding analysis in the form of a theorem.
Theorem 3.1. Suppose
(i) R0 > 1.
(ii)
[
(d2 + d3)
(
s
T∗
+ rT
∗
Tmax
)
+ d2rI
∗
Tmax
] (
d2 + d3 +
s
T∗
+ rT
∗
Tmax
)
−d2d3I
∗
(
r
Tmax
+ d2
T∗
)
>
0 is satisfied and
(iii) the largest positive simple root of (3.10) is ω0,
then E2, the endemic equilibrium point of the delay model is asymptotically stable
when τ < τ0 and unstable when τ > τ0, where,
τ0 =
1
ω0
arccos
[
(a0ω
2
0 − a2)b2 + (ω
3
0 − a1ω0)b1ω0
b22 + (b1ω0)
2
]
.
At τ passes through the critical point τ = τ0, a family of periodic solutions bifurcates
from E2, that is, a Hopf bifurcation occurs at τ = τ0 .
3.4. Estimation of the length of delay to preserve stability. It should be
noted that the stability of bifurcating periodic orbits cannot be determined from the
previous analysis, that is, in the neighborhood of τ0, existence of periodic solutions
will depend on either for τ > τ0 or for τ < τ0. While investigating the stability of
bifurcating periodic orbits, we now try to estimate the maximum length of delay to
maintain the stability of the limit cycle. For this, we consider the space of real valued
continuous functions, defined on [−τ, ∞), satisfying the initial conditions on [−τ, 0].
Let T (t) = T ∗ +X(t), I(t) = I∗ + Y (t), VI(t) = V
∗
I +Z(t), VNI(t) = V
∗
NI +W (t).
Linearizing the system (2.2) about the equilibrium point E2(T
∗, I∗, V ∗I , V
∗
NI), we get
dX
dt
=
(
r − d1 −
2rT ∗
Tmax
−
rI∗
Tmax
− (1− cη1)αV
∗
I
)
X(t)−
rT ∗
Tmax
Y (t)
− (1− cη1)αT
∗Z(t)
dY
dt
= (1− cη1)αV
∗
I X(t− τ) − d2Y (t) + (1− cη1)αT
∗Z(t− τ)
dZ
dt
=
(
1−
η1 + ηr
2
)
βY (t)− d3Z(t)(3.13)
dW
dt
=
(
η1 + ηr
2
)
βY (t)− d3W (t).
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Using Laplace transform of the linearized system (3.13), we obtain,
(
δ − r + d1 +
2rT∗
Tmax
+ rI
∗
Tmax
+ (1− cη1)αV
∗
I
)
LX(δ) = −
rT∗
Tmax
LY (δ)
−(1− cη1)αT
∗LZ(δ) +X(0)
(δ + d2)LY (δ) = (1− cη1)αe
−δτV ∗I LX(δ)
+(1− cη1)αe
−δτV ∗I K1(δ) + (1 − cη1)αe
−δτT ∗LZ(δ) + (1 − cη1)αe
−δτT ∗K2(δ) + Y (0)
(δ + d3)LZ(δ) =
(
1− η1+ηr2
)
βLY (δ) + Z(0)
(δ + d3)LW (δ) =
(
η1+ηr
2
)
βLY (δ) +W (0)
where, K1(δ) =
∫ 0
−τ
e−δtX(t)dt,K2(δ) =
∫ 0
−τ
e−δtZ(t)dt and LX , LY , LZ and LW are
the Laplace transforms of X(t), Y (t), Z(t) and W (t) respectively.
Applying Nyquist criterion, we obtain the conditions for local asymptotic stability
of E2(T
∗, I∗, V ∗I , V
∗
NI) as [19]
ImH(iµ0) > 0,(3.14)
ReH(iµ0) = 0.(3.15)
where H(δ) = (δ3 + a0δ
2 + a1δ + a2) + e
−δτ (b1δ + b2), µ0 being the smallest positive
root of (3.15). It has already been proved that in the absence of delay, E2 is locally
asymptotically stable, provided (3.7) holds. Then, by virtue of Burlet’s lemma [19],
we can state that for sufficiently small τ > 0, all the eigenvalues will continue to have
negative real parts (by continuity), provided there is a guarantee that no eigenvalues
with positive real parts bifurcates from infinity as τ increases from zero.
Inequality (3.14) and equation (3.15) gives
a2 − a0µ
2
0 = −b2 cos(µ0τ) − b1µ0 sin(µ0τ)(3.16)
−µ30 + a1µ0 > b2 sin(µ0τ) − b1µ0 cos(µ0τ)(3.17)
The sufficient conditions that guarantee that stability is obtained, if (3.16) and (3.17)
are satisfied simultaneously, which we utilize to get an estimate of the length of the
delay. Equation (3.16) gives
a0µ
2
0 = a2 + b2 cos(µ0τ) + b1µ0 sin(µ0τ)(3.18)
Taking the maximum value of a2+ b2 cos(µ0τ)+ b1µ0 sin(µ0τ) subject to | sin(µ0τ)| ≤
1, | cos(µ0τ)| ≤ 1, we get
a0µ
2
0 ≤ |a2|+ |b2|+ |b1|µ0
⇒ a0µ
2
0 − |b1|µ0 − (|a2|+ |b2|) = 0(3.19)
So, if
µ+ =
|b1|+
√
b21 + 4a0(|a2|+ |b2|)
2a0
,
then from (3.19), we have µ0 ≤ µ+.
From inequality (3.17), we get
µ20 ≤ a1 −
b2
µ0
sin(µ0τ) + b1 cos(µ0τ),(3.20)
10 Sandip Banerjee, Ram Keval and Sunita Gakkhar
which continue to hold for sufficiently small τ > 0. Substituting (3.18) in (3.20) and
rearranging we get,
(b2 − a0b1)(cos(µ0τ)− 1) +
(
b1µ0 +
a0b2
µ0
)
sin(µ0τ) < a0a1 − a2 − b2 − a0b1(3.21)
Using the bounds
(b2 − a0b1)(cos(µ0τ) − 1) = 2(b2 − a0b1) sin
2
(µ0τ
2
)
≤
1
2
|b2 − a0b1|µ
2
+τ
2(3.22)
and (
b1µ0 +
a0b2
µ0
)
sin(µ0τ) ≤ (b1µ
2
+ + a0b2)τ(3.23)
we obtain from (3.21), N1τ
2 +N2τ < N3, where,
N1 =
1
2
|b2 − a0b1|µ
2
+, N2 = (b1µ
2
+ + a0b2), N3 = a0a1 − a2 − b2 + a0b1.
Thus, Nyquist criterion holds true for 0 ≤ τ ≤ τ+, where τ+ =
1
2N1
(
−N2 +
√
N22 + 4N1N3
)
,
which gives the maximum length of delay for maintaining the stability of the limit
cycle.
3.5. Direction and stability of the Hopf bifurcation. In the subsection
3.3, we have obtained the condition for Hopf bifurcation at the critical value τj and
succeeded to obtain explicitly the expression for τj by using the normal form and
manifold theory and following the ideas of Hassard et al. [23]. In the coming analysis,
our initial assumption is that the system (2.2) exhibits Hopf bifurcation, which in turn
imples that ±iω are the corresponding purely imaginary roots of the characteristic
equation at the infected equilibrium point E2(T
∗, I∗, V ∗I , V
∗
NI).
Using the transformation u1(t) = T (t) − T
∗, u2(t) = I(t) − I
∗, u3(t) = VI(t) −
V ∗I , u4(t) = VNI(t)−V
∗
NI , xi(t) = ui(τt), (i = 1, 2, 3, 4), τ = τj+µ, the system (2.2)
is converted to a functional differential equation (FDE) in C = C([−1, 0], R4)
dx
dt
= Lµ(xt) + f(µ, xt),(3.24)
where (x1(t), x2(t), x3(t), x4(t))
T ∈ R4 and the mapping Lµ : C → R, f : R×C → R,
are respectively given by
Lµ(φ) = (τj + µ)

r − d1 −
2rT∗
Tmax
− rI
∗
Tmax
− (1− cη1)αV
∗
I −
rT∗
Tmax
−(1− cη1)αT
∗ 0
0 −d2 0 0
0
(
1− ηr+η12
)
β −d3 0
0
(
ηr+η1
2
)
β 0 −d3


φ1(0)
φ2(0)
φ3(0)
φ4(0)

+ (τj + µ)

0 0 0 0
(1− cη1)αV
∗
I 0 (1− cη1)αT
∗ 0
0 0 0 0
0 0 0 0


φ1(−1)
φ2(−1)
φ3(−1)
φ4(−1)

and
f(µ, φ) = (τj + µ)

− r
Tmax
φ21(0)−
r
Tmax
φ1(0)φ2(0)− (1− cη1)αφ1(0)φ3(0)
(1− cη1)αφ1(−1)φ3(−1)
0
0

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By virtue of Riesz representation theorem, we can find a function η(θ, µ) of bounded
variation for θ ∈ [−1, 0], such that
Lµ(φ) =
∫ 0
−1
φ(θ)dη(θ, 0)(3.25)
for φ ∈ C. We choose
η(θ, µ) = (τj + µ)

F − rT
∗
Tmax
−(1− cη1)αT
∗ 0
0 −d2 0 0
0
(
1− ηr+η12
)
β −d3 0
0
(
ηr+η1
2
)
β 0 −d3
 δ(θ)
− (τj + µ)

0 0 0 0
(1− cη1)αV
∗
I 0 (1− cη1)αT
∗ 0
0 0 0 0
0 0 0 0
 δ(θ + 1),(3.26)
where δ is the Dirac delta function. Let
A(µ)φ =
{
dφ(θ)
dθ
, θ ∈ [−1, 0),∫ 0
−1 dη(µ, s1)φ(s1), θ = 0,
and
R(µ)φ =
{
0, θ ∈ [−1, 0),
f(µ, φ), θ = 0,
for φ ∈ C1([−1, 0], R4), then system (3.24) is equivalent to
x˙t = A(µ)xt +R(µ)xt,(3.27)
where xt(θ) = x(t+ θ) for θ ∈ [−1, 0]. Again let
A∗ψ(s1) =
{
− dψ(s1)
ds1
, s1 ∈ (−1, 0],∫ 0
−1
dηT (t, 0)ψ(−t), s1 = 0,
for ψ ∈ C1([−1, 0], (R4)∗). We define a bilinear inner product
〈ψ(s1), φ(θ)〉 = ψ(0)φ(0) −
∫ 0
−1
∫ θ
ξ=0
ψ(ξ − θ)dη(θ)φ(ξ)dξ, [η(θ) = η(θ, 0)](3.28)
A(0) and A∗ are called as adjoint operators. It can be easily shown that ±iω0τj are
eigenvalues of A(0). Therefore, ±iω0τj are also eigenvalues of A
∗.
Let q(θ) = (1, a, b, c1)
T eiω0τjθ be the eigenvector of A(0) corresponding to iω0τj ,
then A(0)q(θ) = iω0τjq(θ). Using (3.25), (3.25), (3.26) and the definition of A(0), we
obtain,
τj

iω0 − F
rT∗
Tmax
(1− cη1)αT
∗ 0
−(1− cη1)αV
∗
I e
−iω0τj iω0 + d2 −(1− cη1)αT
∗e−iω0τj 0
0 −
(
1− ηr+η12
)
β iω0 + d3 0
0 −
(
ηr+η1
2
)
β 0 iω0 + d3
 q(0) =

0
0
0
0

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We can easily obtain q(0) = (1, a, b, c1)
T , where
a =
(iω0 + d3)(1− cη1)αV
∗
I e
−iω0τj
(iω0 + d2)(iω0 + d3)− (1− cη1)
(
1− ηr+η12
)
αβT ∗e−iω0τj
, b =
(
1− ηr+η12
)
βa
(iω0 + d3)
, c1 =
(
ηr+η1
2
)
βa
(iω0 + d3)
.
Again, let q∗(s1) = D(1, a
∗, b∗, c∗1)e
iω0τjs1 be the eigenvector of A∗ corresponding to
−iω0τj . In the similar manner we obtain,
a∗ =
−(iω0 + F )
(1 − cη1)αV ∗I e
−iω0τj
, b∗ =
rT∗
Tmax
+ (−iω0 + d2)a
∗(
1− ηr+η12
)
β
, c∗1 = 0.
To assure 〈q∗, q(θ)〉 = 1, we use (3.28) to calculate D as follows:
〈q∗, q(θ)〉 = D(1, a∗, b∗, c∗1)(1, a, b, c1)
T −
∫ 0
−1
∫ θ
ξ=0
D(1, a∗, b∗, c∗1)e
−iω0τj(ξ−θ)dη(θ)(1, a, b, c1)
T eiω0τjξdξ
= D
{
1 + aa∗ + bb∗ −
∫ 0
−1
(1, a∗, b∗, 0)θeiω0τjθdη(θ)(1, a, b, c1)
T
}
= D
{
1 + aa∗ + bb∗ + τje
−iω0τj (1− cη1)αa∗(V
∗
I + bT
∗)
}
Choosing
D =
1
1 + aa∗ + bb∗ + τjeiω0τj (1− cη1)αa∗(V ∗I + bT
∗)
,
we achieve the property 〈q∗, q(θ)〉 = 1.
To compute the coordinates describing the center manifold C0 at µ = 0, we apply
the idea of Hassard et al. [23]. Denoting xt to be the solution of (3.27) at µ = 0, we
define
z(t) = 〈q∗, xt〉, W (t, θ) = xt(θ)− 2Re{z(t)q(θ)}(3.29)
On center manifold C0, we have
W (t, θ) =W (z(t), z(t), θ),
where
W (z, z, θ) =W20(θ)
z2
2
+W11(θ)zz +W02(θ)
z2
2
+W30(θ)
z3
6
+ ...,(3.30)
z and z are local coordinates for center manifold C0 in the direction of q
∗ and q∗.
The expression W (z, z, θ) will be real provided xt is real and we are interested in real
solutions only. For solution xt ∈ C0 of (3.27), since µ = 0, we have
z˙(t) = iω0τjz + q¯∗(0)f(0,W (z, z, 0) + 2Re{zq(θ)})
.
= iω0τjz + q¯∗(0)f0(z, z).
which is rewritten as
z˙(t) = iω0τjz(t) + g(z, z),
where
g(z, z) = q¯∗(0)f0(z, z) = g20
z2
2
+ g11zz + g02
z2
2
+ g21
z2z
2
+ ...(3.31)
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Then (3.29) and (3.30) gives
xt(θ) =W (t, θ) + 2Re{z(t)q(t)}
=W20(θ)
z2
2
+W11(θ)zz +W02(θ)
z2
2
+ (1, a, b, c1)
T eiω0τjθz
+ (1, a, b, c1)
T e−iω0τjθz + ...,
From the definition of g(z, z) we have
g(z, z) = q¯∗(0)f0(z, z) = q¯∗(0)f(0, xt)
= τjD(1, a∗, b∗, 0)

− r
Tmax
x21t(0)−
r
Tmax
x1t(0)x2t(0)− (1 − cη1)αx1t(0)x3t(0)
(1− cη1)αx1t(−1)x3t(−1)
0
0

= −τjD{
r
Tmax
[
z + z +W
(1)
20 (0)
z2
2
+W
(1)
11 (0)zz +W
(1)
02 (0)
z2
2
+ o(|(z, z)|3)
]2
+
r
Tmax
[
z + z +W
(1)
20 (0)
z2
2
+W
(1)
11 (0)zz +W
(1)
02 (0)
z2
2
+ o(|(z, z)|3)
]
×
[
az + a¯z +W
(2)
20 (0)
z2
2
+W
(2)
11 (0)zz +W
(2)
02 (0)
z2
2
+ o(|(z, z)|3)
]
(3.32)
+ α1
[
be−iω0τjz + beiω0τjz +W
(3)
20 (−1)
z2
2
+W
(3)
11 (−1)zz +W
(3)
02 (−1)
z2
2
+ o(|(z, z)|3)
]
×
[
e−iω0τjz + eiω0τjz +W
(1)
20 (−1)
z2
2
+W
(1)
11 (−1)zz +W
(1)
02 (−1)
z2
2
+ o(|(z, z)|3)
]
}
+ γ
[
be−iω0τjz + beiω0τjz +W
(3)
20 (−1)
z2
2
+W
(3)
11 (−1)zz +W
(3)
02 (−1)
z2
2
+ o(|(z, z)|3)
]
×
[
e−iω0τjz + eiω0τjz +W
(1)
20 (−1)
z2
2
+W
(1)
11 (−1)zz +W
(1)
02 (−1)
z2
2
+ o(|(z, z)|3)
]
Comparing the coefficients with (3.31), we get,
g20 = −2τjD
[
(1 + a)
r
Tmax
+ (1− cη1)αbe
−2iω0τj − (1 − cη1)αba∗e
−2iω0τj
]
g11 = −2τjD
[
(1 +Re(a))
r
Tmax
+ (1− cη1)αRe(b)− (1 − cη1)αRe(b)a∗
]
g02 = −2τjD
[
(1 + a)
r
Tmax
+ (1− cη1)αbe
2iω0τj − (1 − cη1)αba∗e
2iω0τj
]
g21 = −2τjD[2
r
Tmax
W
(1)
11 (0) +
r
Tmax
W
(1)
20 (0) +
r
Tmax
{aW
(1)
11 (0) +
1
2
aW
(1)
20 (0)
+
1
2
W
(2)
20 (0) +W
(2)
11 (0)}+ (1− cη1)α{W
(3)
11 (−1)e
−iω0τj +
1
2
W
(3)
20 (−1)e
iω0τj
+
1
2
bW
(1)
20 (−1)e
iω0τj + bW
(1)
11 (−1)e
−iω0τj} − (1− cη1)αa∗{W
(3)
11 (−1)e
−iω0τj
+
1
2
W
(3)
20 (−1)e
iω0τj +
1
2
bW
(1)
20 (−1)e
iω0τj + bW
(1)
11 (−1)e
−iω0τj}]
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Since W20(θ) and W11(θ) are in the expression of g21, we need to compute them. The
calculation is shown in the Appendix. Furthermore, g21 can be expressed using the
parameters and the delay in the system. Therefore, we can compute
c11(0) =
i
2ω0τj
(
g20g11 − 2|g11|
2 −
|g02|
2
3
)
+
g21
2
,
µ2 = −
Re{c11(0)}
Re{λ′(τj)}
,
β2 = 2Re(c11(0)) and(3.33)
T2 = −
Im{c11(0)}+ µ2Im{λ
′
(τj)}
ω0τj
.
The expressions in (3.33) gives the quantification of the bifurcating periodic solutions
in the center manifold at the critical value (τ0) of the time lag. The direction of the
Hopf bifurcation is determined from the sign of µ2. The Hopf bifurcation is forward
or backward according as µ2 > 0 or µ2 < 0 and the bifurcating periodic solution
exists for τ > τ0 and τ > τ0 respectively. The sign of β2 quantifies the stability of the
bifurcating periodic solution; for β2 < 0, the solution is stable and unstable if β2 > 0.
Finally, T2 determines the period of the bifurcating periodic solution. The period is
increasing if T2 > 0 and decreasing if T2 < 0.
4. Numerical results and its biological implications. We now simulate the
system (2.2) to observe the effect of intracellular delay on the dynamics of hepatitis C
virus with therapy. We verify our model with two sets of parameter obtained from [10]
(see table 1 and 2), starting with parameter set 1. We have taken the viral replication
time (τ) in the range of 24 hours to 36 hours [16, 22]. Throughout the discussion, we
have considered η as the combined drug efficacy, given by
1− η = (1− cη1)
(
1−
ηr + η1
2
)
,
along with ηc, the critical drug efficacy. Our discussion will revolve around R0, the
basic reproduction number and its relation with the critical drug efficacy ηc. Please
note, the initial viral load for numerical simulation is 107 copies/ml, which is around
the endemic equilibrium point and hence
R0 > 1 ⇒
Tˆ
T ∗
> 1 ⇒ Tˆ
αβ(1 − η)
d2d3
> 1
⇒ η < 1−
d2d3
αβTˆ
= ηc(4.1)
This implies when η < ηc, R0 > 1 and the viral load reaches the endemic equilibrium
point. But, when η > ηc, R0 < 1, the endemic equilibrium point becomes negative
and exchanges stability with the uninfected steady state and disease free equilibrium
point is achieved.
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Table 1
Parameter Parameter values Units
s 1.0 cells day−1 ml−1[10]
r 2.0 day−1[10]
Tmax 3.6× 10
7 cells ml−1[10]
α 2.25× 10−7 ml virions−1 day−1[10]
β 2.9 virions day−1[10]
d1 0.01 day
−1[10]
d2 1.0 day
−1[10]
d3 6.0 day
−1[10]
Table 2
Parameter Parameter values Units
s 3.7× 104 cells day−1 ml−1 [10]
r 0.73 day−1 [10]
Tmax 0.6× 10
7 cells ml−1 [10]
α 1.8× 10−7 ml virions−1 day−1 [10]
β 13.9 virions day−1 [10]
d1 2.4× 10
−3 day−1 [10]
d2 0.06 day
−1 [10]
d3 13.9 day
−1 [10]
Effect of interferon monotherapy: We first consider interferon, a mixture
of proteins, having antiviral and immunomodulating effects, to illustrates interferon
monotherapy on viral dynamics in the presence of intracellular delay. Hepatitis C
virus declines as well as the dynamics of infected and uninfected hepatocytes are
shown in figure 4.1.
The viral decline is biphasic in nature, mimicking the kinetics of the viral decline
in patients responding to interferon monotherapy. From the figure we conclude that
the first phase decline occurs for about (48-52) hours, following by a slow second phase
decline starting at 52 hours. This behavior has been observed clinically [25, 34]. The
wavy nature of the second phase decline is due to the effect of intracellular delay.
As the viral load declines, the infected hepatocytes also decline and the number of
uninfected hepaocytes reaches large steady state value. However, the standard inter-
feron regime sometimes fails to control HCV, which are the case of non-responders.
This dynamics has been portrayed in figure 4.2, where there is a first phase decline
followed by a flat phase, that is, the viral load approaches an endemic steady state.
The infectious hepatocytes and noninfectious viruses also exhibit the same behavior.
Please note, though the interferon efficacy is high (η1 = 0.80), the combined efficacy
η = 0.64 < ηc(= 0.745). Since, η < ηc implies R0 > 1, the viral load showing minor
decline will never converge to E0 and ultimately converge to a new steady state. This
means that in non-responders, the efficacies due to interferon fail to reach the critical
drug efficacy, and this has been confirmed clinically too [4, 3].
Effect of ribavirin monotherapy: Ribavirin monotherapy has not been effec-
tive for the treatment of hepatitis C viral infection and our model also certifies that.
The effect of ribavirin monotherapy on HCV is shown in figure 4.3, where ribavirin
fails to clear the viral load. Even though the efficacy of ribavirin is 0.98 (figure 4.3),
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its combined efficacy as calculated by is 0.68, which is less than ηc(= 0.745), implying
R0 > 1. Several experiments have been conducted [12, 11, 5] to evaluate the effect
of ribavirin for the treatment of hepatitis C virus but no virologic end of treatment
response (ETR) were observed in all these experiments. In most of these cases, HCV
RNA level remains constant after 3-6 months of ribavirin monotherapy compared
within pretreatment values [12, 11].
Effect of combined therapy: To achieve the goal of minimizing the viral load
of HCV, current standard treatment consists of the combination of pegylated inter-
feron and ribavirin [26]. Thus, we conclude that when interferon efficacy is small,
ribavirin enhances treatment level by turning progeny virions non-infections, result-
ing in a second phase decline and the patient attains SVR, that is, the concentration
of the virus in the patient’s blood falls below the detection limit (100 copies/ml)
during the combined therapy (figure 4.4). Experimental observation also confirm
this fact [24, 26, 31]. The combined therapy of pegylated interferon and ribavirin
also results in triphasic decline of viral load in some patients [24]. Figure 4.5 shows
triphasic decline where the first phase shows a sharp drop in the viral load followed by
a shoulder second phase (flat phase) after which the viral load decline continues in os-
cillations (third phase decline) and the patient attains SVR in approximately 25 days.
Figure 4.6 shows that the dynamics of our model are in agreement with the
behavioral pattern of HCV in 12 patients obtained from the study, conducted at
the University of Sao Paulo Hospital das clinicas and was approved by the ethics
in research committee [9]. The patients were treated with pegylated interferon and
ribavirin for 48 weeks and their detailed analysis were recorded (denoted by ∗ in the
figure). Figure A, B, C, D, E, F, G, H, I show the behavior of HCV RNA levels during
the first 12-14 weeks of PEG-IFN-α-2a monotherapy. The graph obtained from the
model (continuous line) matches with the patient data (∗) [9]. Figure J is the case of
non-responders and figures K and L are the case of non-SVR.
We next consider the second set of parameters given in the table 2, for verification
of the model (2.2). With these set of parameters, theorem 3.1 holds. It is observed
that without delay there exist a unique interior equilibrium point E2, which is locally
asymptotically stable. Using the same set of parameters, we obtain, we A1 > 0
and A3 < 0, which indicates the existence of a positive root. We also calculate
w0 = 0.07321 by solving (3.10). Following theorem 1 in [7], we can say that stability
switch may occur as the value of τ increases. In this case stability switch occurs at
τ0 = 24.1 hours (calculated from (3.12) by putting j = 0), where the dynamics of the
system changes from a stable steady state to stable oscillatory state. The calculated
value of τ0 also certifies our analytical estimation of the length of delay to preserve
stability. Therefore, by Butler’s lemma, E2 remains stable for τ < τ0 (= 24.1 hours).
For τ = 24.1 hours Hopf bifurcation occurs resulting in stable periodic solution and at
the bifurcated point, a stable limit cycle is formed (figure 4.7). We observe a stability
switch as τ crosses the threshold (τ = 24.1) hours and shows aperiodic solutions.
Please note that we have not provided figures for τ < τ0 and τ > τ0 as these values
of τ0 are unrealistic as far as the patient’s data are concerned.
5. Summary and Discussions. Several studies have used mathematical mod-
els to provide insights into the mechanism and dynamics of the progression of hepatitis
C viral infection. It is of both mathematical and biological interest to determine the
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Fig. 4.1. Interferon monotherapy in presence of intracellular delay (τ = 22.0 hours), where the
parameter set is taken from Table 1. with initial conditions (107, 107, 107, 107). The dynamics of all
the state variables is shown in the figure. The hepatitis C viral load declines, which is biphasic in
nature. From the start of the therapy, the first phase of virus decline occurs for (48-52) hours followed
by a slow second phase till the patient reaches SVR in 36 days (shown by intersection of arrows).
The infected hepatocytes and non-infectious virus also follow the same pattern of decline. The
wavy nature of the decline is due to the presence of intracellular delay. The uninfected hepatocytes
reaches a high steady state value ranging between (107 − 108) cells, which has been observed in
healthy patients. Please note that the uninfected hepatocytes though starts with the initial value
of 107 cells, sharply declines when the viral load is high initially and regains its normal range once
SVR has been achieved.
cause of sustained oscillation, which can be the result of intracellular delay. The main
goal of this paper is to investigate how the delay affects the overall disease progression
and mathematically, how the dynamics of the system is affected by the delay.
We have studied a modified HCV model with four state variables, namely, tar-
get cells, infected hepatocytes, infected and non-infected virions, along with an in-
tracellular delay and combined drug therapy (interferon and ribavirin). The basic
reproduction number of the hepatitis C virus has been used largely in understanding
the dynamics of the viral infection. The influence of time delay on the stability of
the equilibrium states has been discussed. We have proved that the local stability of
the disease free steady state is independent of the delay. However, for the endemic
equilibrium state, an increase in delay can destabilize the system, leading to hopf
bifurcation and periodic solutions. The estimation of the length of delay to preserve
stability has been obtained. Also, the direction and stability of the Hopf bifurcation
have been studied.
The numerical study of the system focused on two aspects, namely, the dynamics
of the system on two different parameter sets and validation of the model with the
virus behavioral pattern of 12 patients, under the influence of interferon monotherapy
and combined therapy with ribavirin. Our results mimic the behavior of HCV in
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Fig. 4.2. Non-responders in the case of Interferon monotherapy in presence of intracellular
delay (τ = 22.0 hours), where the parameter set is taken from Table 1. with initial conditions
(107, 107, 107, 107). There is a short first phase decline, followed by a flat phase, where the hepatitis
C virus ceases to decline and reaches the endemic steady state. This means that the drug interferon
fails to reach the critical drug efficacy, so needed to eradicate hepatitis C virus and achieve SVR.
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Fig. 4.3. Ribavirin monotherapy in presence of intracellular delay (τ = 22.0 hours), where the
parameter set is taken from Table 1. with initial conditions (107, 107, 107, 107). The dynamics of all
the state variables is shown in the figure, where ribavirin fails to clear the viral load and hepatitis C
virus remains more or less constant during the therapy.
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Fig. 4.4. Dynamics of hepatitis C virus during combined therapy in presence of intracellular
delay (τ = 22.0 hours), where the parameter set is taken from Table 1 with initial conditions
(107, 107, 107, 107). From the figure it is observed that when interferon efficacy is small, ribavirin
enhances treatment level by turning infectious virus to non-infectious and the concentration of virus
in the patient’s blood falls below the detection limit of 100 copies/ml. The pattern of decline is wavy
due to the delay effect and the patient attains SVR in 31 days (shown by intersection of arrows),
which is a little faster than interferon monotherapy.
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Fig. 4.5. Triphasic decline in hepatitis C viral dynamics in presence of intracellular delay (τ =
22.0 hours), where the parameter set is taken from Table 1 with initial conditions (107, 107, 107, 107).
The first phase decline occurs for (24-36) hours followed by a shoulder (flat) phase, which continues
for (1.5-5) days. Thus, there is a third phase decline, which happens in oscillation due to the presence
of delay and SVR is achieved in 25 days.
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Fig. 4.6. Model validation with data obtained from 12 patients who were undergoing treatment
with PEG-IFN-α-2a serum concentration at the University of Sao Paulo hospital das clinicas. The
hepatitis C virus behavioral data of the patients which are shown in ∗ are obtained from [9], page 464,
figure2. In this figure, A-I are the responses of the model with interferon monotherapy (continuous
line) which matches with the data (∗). J is non-responder, K and L are non-SVR. All the parameter
values are taken from Table 1, with tau = 22 hours.
patients observed clinically with the first set of data given in the table 1. The second
set of data actually calculate a discrete time delay τ0, for which we get a Hopf bifurca-
tion resulting in stable periodic solution. It is numerically observed that with proper
choice of drug efficacies, hepatitis C virus can be controlled. Please note that a Hopf
bifurcation was not found in a realistic parameter space with data set 1 but with data
set 2, our analytical finding on the existence of a hopf bifurcation with biologically
realistic parameters remain true. In the future, we would like to extend this work for
different types of delays such as distributed delays or multiple discrete delays. Also,
there are many components in this model that may be regarded as stochastic rather
than deterministic and these variations may significantly alter the dynamics of the
system. We, therefore, suggest to convert the system given by (2.2) into a stochastic
delay differential equations and study its dynamics, which we propose as our future
work.
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Fig. 4.7. The figure shows the dynamics of hepatitis C virus with intracellular delay τ = 24.1
hours (= τ0), η1 = 0.5, ηr = 0.7, c = 0.81, where the system exhibits Hopf bifurcation. As ηr is
increased to 0.75, 0.8, 0.85, 0.9 and 0.95, decline in viral load has been observed (B, C, D, E, F). All
the parameter values are taken from Table 2.
Appendix: Calculation of W20(θ) and W11(θ). From (3.27) and (3.29), we
have
W˙ = x˙t − z˙q − ˙¯zq¯ =
{
AW − 2Re{q¯∗(0)f0q(θ)}, ifθ ∈ [−1, 0),
AW − 2Re{q¯∗(0)f0q(0)}+ f0, ifθ = 0,
(5.1)
= AW +H(z, z¯, θ) (say),
where
H(z, z¯, θ) = H20(θ)
z2
2
+H11(θ)zz +H02(θ)
z2
2
+ ...(5.2)
Substituting the corresponding series into (5.1) and comparing the coefficients, we
obtain
(A− 2iτ0ω0)W20(θ) = −H20(θ), AW11(θ) = −H11(θ), ...(5.3)
From (5.1), we know that for θ ∈ [−1, 0),
H(z, z¯, θ) = −q¯∗(0)f0q(θ)− q
∗(0)f¯0q¯(θ) = −g(z, z¯)q(θ) − g¯(z, z¯)q¯(θ).(5.4)
22 Sandip Banerjee, Ram Keval and Sunita Gakkhar
Comparing the corresponding coefficients with that of (5.2), we get,
H20(θ) = −g20q(θ) − g¯02q¯(θ), H11(θ) = −g11q(θ)− g¯11q¯(θ).(5.5)
From (5.3),(5.5) and the definition of A, it follows that
W˙20(θ) = 2iω0τkW20(θ) + g20(θ)q(θ) + g¯02q¯(θ).
Note that q(θ) = (1, a, b, c1)
T eiω0τjθ, hence
W20(θ) =
ig20
ω0τj
q(0)eiω0τjθ +
ig¯02
3ω0τj
q¯(0)e−iω0τjθ + E1e
2iω0τjθ,(5.6)
Here E1 = (E
(1)
1 , E
(2)
1 , E
(3)
1 , E
(4)
1 ) ∈ R
4 is a constant vector. Similarly, from (5.3) and
(5.6), we get
W11(θ) = −
ig11
ω0τj
q(0)eiω0τjθ +
ig¯11
3ω0τj
q¯(0)e−iω0τjθ + E2,(5.7)
where E2 = (E
(1)
2 , E
(2)
2 , E
(3)
2 , E
(4)
2 ) ∈ R
4 is also a constant vector. Now, we have to
find an appropriate constant vector E1 and E2 which satisfy the above conditions.
From the definition of A and (5.3), we obtain∫ 0
−1
dη(θ)W20(θ) = 2iω0τjW20(θ) −H20(θ),(5.8)
and ∫ 0
−1
dη(θ)W11(θ) = −H11(0),(5.9)
where η(θ) = η(0, θ). Using (5.1), we have
H20(0) = −g20q(0)− g¯20q¯(0) + 2τj

−(1 + a) r
Tmax
− (1− cη1)αbe
−2iω0τj
(1− cη1)αbe
−2iω0τj
0
0
(5.10)
and
H11(0) = −g11q(0)− g¯11q¯(0) + 2τj

−(1 +Re(a)) r
Tmax
− (1 − cη1)αRe(b)
(1 − cη1)αRe(b)
0
0
(5.11)
Substituting (5.6) and (5.10) into (5.8), we obtain
(
2iω0τjI −
∫ 0
−1
e2iω0τjθdη(θ)
)
E1 = 2τj

−(1 + a) r
Tmax
− (1− cη1)αbe
−2iω0τj
(1 − cη1)αbe
−2iω0τj
0
0

which leads to
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
iω0 − F
rT∗
Tmax
(1 − cη1)αT
∗ 0
−(1− cη1)αV
∗
I e
−iω0τj iω0 + d2 −(1− cη1)αT
∗e−iω0τj 0
0 −
(
1− ηr+η12
)
β iω0 + d3 0
0 −
(
ηr+η1
2
)
β 0 iω0 + d3


E
(1)
1
E
(2)
1
E
(3)
1
E
(4)
1

= 2

−(1 + a) r
Tmax
− (1− cη1)αbe
−2iω0τj
(1− cη1)αbe
−2iω0τj
0
0

From above, we can easily calculate a constant vector E1 = (E
(1)
1 , E
(2)
1 , E
(3)
1 , E
(4)
1 ) ∈
R4. Similarly, substituting (5.7) and (5.11) into (5.9), we can get
F − rT
∗
Tmax
−(1− cη1)αT
∗ 0
−(1− cη1)αV
∗
I −d2 −(1− cη1)αT
∗ 0
0
(
1− ηr+η12
)
β −d3 0
0
(
ηr+η1
2
)
β 0 −d3


E
(1)
2
E
(2)
2
E
(3)
2
E
(4)
2

= 2

−(1 +Re(a)) r
Tmax
− (1 − cη1)αRe(b)
(1− cη1)αRe(b)
0
0

In the similar manner, we can calculate the constant vectorE2 = (E
(1)
2 , E
(2)
2 , E
(3)
2 , E
(4)
2 ) ∈
R4.
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